ZA9695B - Estrogen agonists/antagonists - Google Patents
Estrogen agonists/antagonistsInfo
- Publication number
- ZA9695B ZA9695B ZA9695A ZA9695A ZA9695B ZA 9695 B ZA9695 B ZA 9695B ZA 9695 A ZA9695 A ZA 9695A ZA 9695 A ZA9695 A ZA 9695A ZA 9695 B ZA9695 B ZA 9695B
- Authority
- ZA
- South Africa
- Prior art keywords
- antagonists
- estrogen agonists
- estrogen
- agonists
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
- C07D207/34—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/36—Oxygen or sulfur atoms
- C07D207/40—2,5-Pyrrolidine-diones
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/62—Oxygen or sulfur atoms
- C07D213/63—One oxygen atom
- C07D213/64—One oxygen atom attached in position 2 or 6
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/30—Oestrogens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/32—Antioestrogens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
- C07D217/12—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with radicals, substituted by hetero atoms, attached to carbon atoms of the nitrogen-containing ring
- C07D217/14—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with radicals, substituted by hetero atoms, attached to carbon atoms of the nitrogen-containing ring other than aralkyl radicals
- C07D217/16—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with radicals, substituted by hetero atoms, attached to carbon atoms of the nitrogen-containing ring other than aralkyl radicals substituted by oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
- C07D295/08—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms
- C07D295/084—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
- C07D295/088—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings to an acyclic saturated chain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
- C07D295/14—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D295/155—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with the ring nitrogen atoms and the carbon atoms with three bonds to hetero atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Diabetes (AREA)
- Physical Education & Sports Medicine (AREA)
- Endocrinology (AREA)
- Rheumatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Hematology (AREA)
- Epidemiology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Obesity (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US08/369,954 US5552412A (en) | 1995-01-09 | 1995-01-09 | 5-substitued-6-cyclic-5,6,7,8-tetrahydronaphthalen2-ol compounds which are useful for treating osteoporosis |
Publications (1)
Publication Number | Publication Date |
---|---|
ZA9695B true ZA9695B (en) | 1997-07-08 |
Family
ID=23457628
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ZA9695A ZA9695B (en) | 1995-01-09 | 1996-01-08 | Estrogen agonists/antagonists |
Country Status (46)
Families Citing this family (178)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6974796B1 (en) | 1999-08-17 | 2005-12-13 | Girsh Leonard S | Therapeutic compositions for treatment of a damaged tissue |
US5552412A (en) | 1995-01-09 | 1996-09-03 | Pfizer Inc | 5-substitued-6-cyclic-5,6,7,8-tetrahydronaphthalen2-ol compounds which are useful for treating osteoporosis |
UA51676C2 (uk) * | 1995-11-02 | 2002-12-16 | Пфайзер Інк. | (-)цис-6(s)-феніл-5(r)[4-(2-піролідин-1-ілетокси)феніл]-5,6,7,8-тетрагідронафталін-2-ол d-тартрат, спосіб його одержання, спосіб лікування захворювань, що піддаються лікуванню агоністами естрогену, та фармацевтична композиція |
TW442286B (en) * | 1996-02-28 | 2001-06-23 | Pfizer | New therapeutic uses of estrogen agonists |
HN1996000101A (es) | 1996-02-28 | 1997-06-26 | Inc Pfizer | Terapia combinada para la osteoporosis |
IL120266A (en) * | 1996-02-28 | 2005-05-17 | Pfizer | Use of estrogen antagonists and estrogen agonists in the preparation of medicaments for inhibiting pathological conditions |
IL120265A0 (en) * | 1996-02-28 | 1997-06-10 | Pfizer | Combination therapy to treat osteoporosis - polyphosphonates or progestins and estrogen agonists |
CA2206752A1 (en) * | 1996-07-02 | 1998-01-02 | George Joseph Cullinan | Benzothiophene compounds, intermediates, processes, and methods of use |
ID19392A (id) | 1996-08-29 | 1998-07-09 | Lilly Co Eli | Senyawa naftil dan bahan pertengahan serta komposisi dan metode penggunaan |
CA2215856A1 (en) * | 1996-09-26 | 1998-03-26 | Eli Lilly And Company | Dihydrobenzofluorene compounds, intermediates, compositions, and methods |
CA2215647A1 (en) * | 1996-10-24 | 1998-04-24 | Eli Lilly And Company | Naphthyl compounds, compositions, and methods |
US6034102A (en) * | 1996-11-15 | 2000-03-07 | Pfizer Inc | Atherosclerosis treatment |
WO1998048806A1 (en) * | 1997-04-25 | 1998-11-05 | Eli Lilly And Company | Indene compounds having activity as serms |
CA2236254A1 (en) * | 1997-04-30 | 1998-10-30 | David Warren Hoard | Process for preparing benzo¬b|thiophenes |
WO1998048792A1 (en) * | 1997-04-30 | 1998-11-05 | Eli Lilly And Company | A REGIOSELECTIVE ALKYLATION PROCESS FOR PREPARING SUBSTITUTED BENZO[b]THIOPHENES |
CA2287920A1 (en) * | 1997-04-30 | 1998-11-05 | Eli Lilly And Company | Intermediates and a process for preparing benzo¬b|thiophenes |
JP2001523253A (ja) * | 1997-04-30 | 2001-11-20 | イーライ・リリー・アンド・カンパニー | ベンゾ[b]チオフェン類の製造のための中間体および方法 |
CA2231013A1 (en) * | 1997-04-30 | 1998-10-30 | Eli Lilly And Company | Process for preparing benzoic acid derivative intermediates and benzothiophene pharmaceuticals |
HUP0003187A3 (en) * | 1997-04-30 | 2002-04-29 | Lilly Co Eli | Substituted benzothiophenes and process for preparing them |
US6509356B1 (en) | 1997-08-07 | 2003-01-21 | Eli Lilly And Company | 1-(4-(Substituted alkoxy)benzyl)naphthalene compounds having estrogen inhibitory activity |
US6107346A (en) * | 1997-08-11 | 2000-08-22 | Eli Lilly And Company | Methods for treating hyperlipidemia |
US5908859A (en) * | 1997-08-11 | 1999-06-01 | Eli Lilly And Company | Benzothiophenes for inhibiting hyperlipidemia |
US6080773A (en) | 1997-10-14 | 2000-06-27 | Akzo Nobel, N.V. | Benzylamine derivatives which are useful in treating psychiatric disorders |
US20020037885A1 (en) * | 1999-07-22 | 2002-03-28 | Dijcks Fredericus Antonius | Therapeutic compounds |
US6384058B1 (en) | 1997-12-11 | 2002-05-07 | American Home Products Corporation | 2,4,6-trisubstituted pryridines with estrogenic activity and methods for the solid phase synthesis thereof |
AU3352899A (en) * | 1997-12-11 | 1999-07-12 | American Home Products Corporation | 2,4,6-trisubstituted pyridines with estrogenic activity and methods for the solid phase synthesis thereof |
FR2778404B1 (fr) * | 1998-05-06 | 2000-06-30 | Hoechst Marion Roussel Inc | Derives du dihydro ou tetrahydronaphtalene, et les compositions pharmaceutiques les renfermant |
PA8471201A1 (es) * | 1998-06-16 | 2000-09-29 | Pfizer Prod Inc | Combinaciones terapeuticas que comprenden un modulador del receptor de estrogenos selectivo y hormona paratiroidea |
DE69916932T2 (de) | 1998-06-16 | 2005-04-21 | Pfizer Prod Inc | Kombinationstherapeutika, enthaltend einen selektiven Östrogenrezeptormodulator und Prostaglandin E2 |
DE19833786A1 (de) * | 1998-07-18 | 2000-01-20 | Schering Ag | Benzocycloheptene, Verfahren zu ihrer Herstellung, pharmazeutische Präparate, die diese enthalten, sowie deren Verwendung zur Herstellung von Arzneimitteln |
EP1004306A3 (en) * | 1998-08-06 | 2000-06-07 | Pfizer Products Inc. | Estrogen agonists/antagonists |
US6503917B1 (en) | 1998-12-10 | 2003-01-07 | Wyeth, Five Giralda Farms | 2,4,6-trisubstituted pyridines with estrogenic activity and methods for the solid phase synthesis thereof |
US6291456B1 (en) | 1998-12-30 | 2001-09-18 | Signal Pharmaceuticals, Inc. | Compounds and methods for modulation of estrogen receptors |
US6331562B1 (en) | 1998-12-30 | 2001-12-18 | Signal Pharmaceuticals, Inc. | Compounds and methods for modulation of estrogen receptors |
EP1163225A1 (en) * | 1999-03-17 | 2001-12-19 | Signal Pharmaceuticals, Inc. | Compounds and methods for modulation of estrogen receptors |
US6593322B1 (en) | 1999-03-17 | 2003-07-15 | Signal Pharmaceuticals, Inc. | Compounds and methods for modulation of estrogen receptors |
US6355648B1 (en) | 1999-05-04 | 2002-03-12 | American Home Products Corporation | Thio-oxindole derivatives |
US6509334B1 (en) * | 1999-05-04 | 2003-01-21 | American Home Products Corporation | Cyclocarbamate derivatives as progesterone receptor modulators |
US6391907B1 (en) | 1999-05-04 | 2002-05-21 | American Home Products Corporation | Indoline derivatives |
YU26700A (sh) * | 1999-05-24 | 2002-06-19 | Pfizer Products Inc. | Postupak za cis-1-(2-(4-(6-metoksi-2-fenil-1,2,3,4- tetrahidronaftalen-1-il)fenoksi)etil)pirolidin |
EP1196163B1 (en) * | 1999-07-06 | 2009-11-11 | Endorecherche Inc. | Pharmaceutical compositions for the treatment of insulin resistance |
EP1086692A3 (en) * | 1999-07-28 | 2003-07-09 | Pfizer Products Inc. | Estrogen agonists and antagonists for multiple indications |
US20070037777A1 (en) * | 2005-08-12 | 2007-02-15 | Immunopath Profile, Inc. | Lipid-containing compositions and methods of using them |
US7790678B1 (en) * | 1999-08-17 | 2010-09-07 | Immunopath Profile, Inc. | Composition with anti-inflammatory, protein synthesizing, enzyme deficiency activating genetic therapy and anti-cancer activity and methods of use |
US6436977B1 (en) * | 1999-09-29 | 2002-08-20 | Pfizer Inc. | Dosing regimens for lasofoxifene |
US6566081B1 (en) | 1999-10-06 | 2003-05-20 | The Brigham And Women's Hospital, Inc. | Methods of identifying a compound which modulates the non-transcriptional non-map-kinase induced effects of steroid hormones |
EP1113007A1 (en) * | 1999-12-24 | 2001-07-04 | Pfizer Inc. | Tetrahydroisoquinoline compounds as estrogen agonists/antagonists |
CO5271696A1 (es) * | 2000-01-12 | 2003-04-30 | Pfizer Prod Inc | Procedimiento para reducir la morbilidad y el riesgo de mortalidad |
CO5271697A1 (es) | 2000-01-12 | 2003-04-30 | Pfizer Prod Inc | Composiciones y procedimientos para el tratamiento de afecciones que responden a un aumento de testosterona |
CO5271709A1 (es) * | 2000-01-12 | 2003-04-30 | Pfizer Prod Inc | Composiciones y procedimientos para el y tratamiento de afecciones que responden a estrogenos |
CO5251465A1 (es) * | 2000-01-26 | 2003-02-28 | Pfizer Prod Inc | Composiciones y procedimientos para tratar la osteoporosis y reducir el colesterol |
CA2405070A1 (en) | 2000-04-07 | 2001-10-18 | Pfizer Products Inc. | Estrogen agonist/antagonist metabolites |
US20020013327A1 (en) * | 2000-04-18 | 2002-01-31 | Lee Andrew G. | Compositions and methods for treating female sexual dysfunction |
ES2274854T3 (es) * | 2000-05-08 | 2007-06-01 | Pfizer Products Inc. | Resolucion enzimatica de moduladores selectivos del receptor de estrogeno. |
ES2210168T3 (es) * | 2000-06-01 | 2004-07-01 | Watson Pharmaceuticals, Inc. | Dispositivo transdermico de lasofoxileno. |
AR029538A1 (es) | 2000-07-06 | 2003-07-02 | Wyeth Corp | Composiciones farmaceuticas de agentes estrogenicos |
EP1192945A3 (en) * | 2000-09-21 | 2004-03-03 | Pfizer Products Inc. | Use of an estrogen agonist/antagonist for treating osteoarthritis |
JP2002117407A (ja) * | 2000-10-10 | 2002-04-19 | Satake Corp | 動画像検索方法及びその装置 |
IL145838A (en) * | 2000-10-16 | 2008-11-03 | Pfizer Prod Inc | Use of an estrogen agonist / antagonist to produce a drug for the treatment of vaginitis |
IL145876A0 (en) | 2000-10-17 | 2002-07-25 | Pfizer Prod Inc | Methods and kits for improving vascular health |
EP1210951B1 (en) * | 2000-11-30 | 2005-02-02 | Pfizer Products Inc. | Composition containing estrogen agonists/antagonists and testosterone for treating a decline in the level of the hormone testosterone |
JP2004515494A (ja) | 2000-12-07 | 2004-05-27 | アストラゼネカ・アクチエボラーグ | 治療剤 |
WO2002056903A2 (en) * | 2001-01-17 | 2002-07-25 | Praecis Pharmaceuticals Inc. | Methods for treating hormone associated conditions using a combination of lhrh antagonists and specific estrogen receptor modulators |
AU781168B2 (en) * | 2001-01-26 | 2005-05-12 | Pfizer Products Inc. | Method of treating certain cancers using an estrogen agonist/antagonist |
US6599921B2 (en) | 2001-02-22 | 2003-07-29 | Nanodesign, Inc. | Non-steroidal estrogen receptor ligands |
AU2756602A (en) * | 2001-04-25 | 2002-10-31 | Pfizer Products Inc. | Methods and kits for treating depression or preventing deterioration of cognitive function |
US20020182646A1 (en) * | 2001-04-30 | 2002-12-05 | Ke Huazhu | Methods and products for identifying modulators of P2X7 receptor activity, and their use in the treatment of skeletal disorders |
SK286536B6 (sk) * | 2001-05-01 | 2008-12-05 | Pfizer Products Inc. | Spôsob granulácie za sucha na prípravu farmaceutickej kompozície |
US7425565B2 (en) * | 2002-05-09 | 2008-09-16 | Cedars-Sinai Medical Center | Use of benzothiopenes to treat and prevent prostate cancer |
ATE367812T1 (de) | 2001-06-20 | 2007-08-15 | Wyeth Corp | Substituierte indolsäurederivate als inhibitoren von plasminogen-aktivator-inhibitor-1 (pai-1) |
TWI224101B (en) | 2001-06-20 | 2004-11-21 | Wyeth Corp | Substituted naphthyl indole derivatives as inhibitors of plasminogen activator inhibitor type-1 (PAI-1) |
US7183410B2 (en) * | 2001-08-02 | 2007-02-27 | Bidachem S.P.A. | Stable polymorph of flibanserin |
US20030060475A1 (en) * | 2001-08-10 | 2003-03-27 | Boehringer Ingelheim Pharma Kg | Method of using flibanserin for neuroprotection |
EP1312363A1 (en) * | 2001-09-28 | 2003-05-21 | Pfizer Products Inc. | Methods of treatment and kits comprising a growth hormone secretagogue |
AU2002365132A1 (en) | 2001-10-17 | 2003-07-15 | Bristol-Myers Squibb Company | BICYCLIC LACTAM DERIVATIVES AS INHIBITORS OF MATRIX METALLOPROTEINASES AND/OR TNF-Alpha CONVERTING ENZYME (TACE) |
UA78974C2 (en) | 2001-10-20 | 2007-05-10 | Boehringer Ingelheim Pharma | Use of flibanserin for treating disorders of sexual desire |
US10675280B2 (en) | 2001-10-20 | 2020-06-09 | Sprout Pharmaceuticals, Inc. | Treating sexual desire disorders with flibanserin |
US20050080143A1 (en) * | 2001-11-29 | 2005-04-14 | Steiner Mitchell S. | Treatment of androgen-deprivation induced osteoporosis |
US20060269611A1 (en) * | 2001-11-29 | 2006-11-30 | Steiner Mitchell S | Prevention and treatment of androgen-deprivation induced osteoporosis |
US7524866B2 (en) * | 2001-11-29 | 2009-04-28 | Gtx, Inc. | Prevention and treatment of androgen—deprivation induced osteoporosis |
US20040213841A1 (en) * | 2001-11-29 | 2004-10-28 | Steiner Mitchell S | Methods for treating hot flashes and gynecomastia |
US20080249183A1 (en) * | 2001-11-29 | 2008-10-09 | Steiner Mitchell S | Treatment of androgen-deprivation induced osteoporosis |
US20070197664A1 (en) * | 2001-11-29 | 2007-08-23 | Steiner Mitchell S | Prevention and treatment of androgen-deprivation induced osteoporosis |
US20040096510A1 (en) * | 2001-11-29 | 2004-05-20 | Steiner Mitchell S. | Prevention and treatment of androgen-deprivation induced osteoporosis |
US20040214898A1 (en) * | 2001-11-29 | 2004-10-28 | Steiner Mitchell S. | Methods for treating hot flashes |
US7342884B2 (en) * | 2002-03-13 | 2008-03-11 | Harmonic, Inc. | Method and apparatus for one directional communications in bidirectional communications channel |
KR100636953B1 (ko) | 2002-03-28 | 2006-10-19 | 화이자 프로덕츠 인코포레이티드 | 정제된 라소폭시펜 및 재결정화에 의한 라세미라소폭시펜의 정제 방법 |
US20040048877A1 (en) * | 2002-05-22 | 2004-03-11 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Pharmaceutical compositions containing flibanserin |
US6608212B1 (en) * | 2002-06-04 | 2003-08-19 | Pfizer, Inc. | Process for preparing vinylaromatic compounds |
PA8576201A1 (es) * | 2002-07-10 | 2004-05-26 | Pfizer Prod Inc | Composicion farmaceutica que tiene una distribucion y potencia uniforme de farmaco |
PL374845A1 (en) | 2002-07-22 | 2005-11-14 | Eli Lilly And Company | Selective estrogen receptor modulators containing a phenylsulfonyl group |
US9315539B2 (en) * | 2002-10-01 | 2016-04-19 | Yale University | 11 beta-short chain substituted estradiol analogs and their use in the treatment of menopausal symptoms and estrogen sensitive cancer |
UA80453C2 (en) | 2002-12-10 | 2007-09-25 | Derivatives of substituted dyhydropyranoindol-3,4-dion as inhibitors of plasminogen activator inhibitor-1 (pai-1) | |
AU2003296324A1 (en) | 2002-12-10 | 2004-06-30 | Wyeth | Aryl, aryloxy, and alkyloxy substituted 1h-indol-3-yl glyoxylic acid derivatives as inhibitors of plasminogen activator inhibitor-1 (pai-1) |
US7056943B2 (en) | 2002-12-10 | 2006-06-06 | Wyeth | Substituted indole oxo-acetyl amino acetic acid derivatives as inhibitors of plasminogen activator inhibitor-1 (PAI-1) |
ES2266907T3 (es) | 2002-12-10 | 2007-03-01 | Wyeth | Derivados sustituidos del acido 3-carbonil-indol-1-il-acetico como inhibidor del activador del plasminogeno-1 (pal-1). |
US7323462B2 (en) | 2002-12-10 | 2008-01-29 | Pfizer Inc. | Morpholine dopamine agonists |
AU2003297727A1 (en) | 2002-12-10 | 2004-06-30 | Wyeth | Substituted 3-alkyl and 3-arylalkyl 1h-indol-1-yl acetic acid derivatives as inhibitors of plasminogen activator inhibitor-1 (pai-1) |
WO2004058682A1 (ja) | 2002-12-26 | 2004-07-15 | Eisai Co., Ltd. | 選択的エストロゲン受容体モジュレーター |
US7332525B2 (en) | 2003-01-17 | 2008-02-19 | Castle Erik P | Method of treatment of prostate cancer and composition for treatment thereof |
WO2004064832A2 (en) * | 2003-01-22 | 2004-08-05 | Pfizer Products Inc. | Methods for treating joint pain or improving sleep using an estrogen agonist/antagonist |
CA2523830A1 (en) * | 2003-04-30 | 2004-11-11 | Debiopharm S.A. | Methods and compositions using gonadotropin hormone releasing hormone |
US20040248989A1 (en) | 2003-06-05 | 2004-12-09 | Risto Santti | Method for the treatment or prevention of lower urinary tract symptoms |
EP1667692A1 (en) * | 2003-09-19 | 2006-06-14 | Pfizer Products Inc. | Pharmaceutical compositions and methods comprising combinations of 2-alkylidene-19-nor-vitamin d derivatives and an estrogen agonist/antagonist |
US7141592B2 (en) | 2003-09-25 | 2006-11-28 | Wyeth | Substituted oxadiazolidinediones |
US7332521B2 (en) | 2003-09-25 | 2008-02-19 | Wyeth | Substituted indoles |
US7268159B2 (en) | 2003-09-25 | 2007-09-11 | Wyeth | Substituted indoles |
US7442805B2 (en) | 2003-09-25 | 2008-10-28 | Wyeth | Substituted sulfonamide-indoles |
US7420083B2 (en) | 2003-09-25 | 2008-09-02 | Wyeth | Substituted aryloximes |
US7163954B2 (en) | 2003-09-25 | 2007-01-16 | Wyeth | Substituted naphthyl benzothiophene acids |
US7411083B2 (en) | 2003-09-25 | 2008-08-12 | Wyeth | Substituted acetic acid derivatives |
US7582773B2 (en) | 2003-09-25 | 2009-09-01 | Wyeth | Substituted phenyl indoles |
US7534894B2 (en) | 2003-09-25 | 2009-05-19 | Wyeth | Biphenyloxy-acids |
US7351726B2 (en) | 2003-09-25 | 2008-04-01 | Wyeth | Substituted oxadiazolidinediones |
US7342039B2 (en) | 2003-09-25 | 2008-03-11 | Wyeth | Substituted indole oximes |
US7446201B2 (en) | 2003-09-25 | 2008-11-04 | Wyeth | Substituted heteroaryl benzofuran acids |
US7265148B2 (en) | 2003-09-25 | 2007-09-04 | Wyeth | Substituted pyrrole-indoles |
EP1696893A1 (en) * | 2003-12-17 | 2006-09-06 | Pfizer Products Incorporated | Continuous combination therapy with selective prostaglandin ep4, receptor agonists and an estrogen for the treatment of conditions that present with low bone mass. |
US20070111988A1 (en) * | 2004-01-22 | 2007-05-17 | Eli Lilly And Company | Selective estrogen receptor modulators |
WO2005073190A1 (en) * | 2004-01-29 | 2005-08-11 | Eli Lilly And Company | Selective estrogen receptor modulators |
US7649002B2 (en) | 2004-02-04 | 2010-01-19 | Pfizer Inc | (3,5-dimethylpiperidin-1yl)(4-phenylpyrrolidin-3-yl)methanone derivatives as MCR4 agonists |
US20050203086A1 (en) * | 2004-03-04 | 2005-09-15 | Pfizer Inc. | Methods of treatment using an EP2 selective receptor agonist |
MXPA06011686A (es) | 2004-04-08 | 2006-12-14 | Wyeth Corp | Ascorbato de bazedoxifeno como modulador del receptor de estrogeno selectivo. |
US20050239798A1 (en) * | 2004-04-22 | 2005-10-27 | Boehringer Ingelheim Pharmaceuticals, Inc. | Method for the treatment of premenstrual and other female sexual disorders |
US7444197B2 (en) | 2004-05-06 | 2008-10-28 | Smp Logic Systems Llc | Methods, systems, and software program for validation and monitoring of pharmaceutical manufacturing processes |
US7799273B2 (en) | 2004-05-06 | 2010-09-21 | Smp Logic Systems Llc | Manufacturing execution system for validation, quality and risk assessment and monitoring of pharmaceutical manufacturing processes |
BRPI0512342A (pt) * | 2004-06-21 | 2008-03-04 | Pharmacia & Upjohn Co Llc | métodos para aumento ósseo |
CA2576747A1 (en) * | 2004-08-17 | 2006-03-02 | Janssen Pharmaceutica N.V. | Benzoxazepine derivatives as selective estrogen receptor modulators |
KR20070045353A (ko) | 2004-08-23 | 2007-05-02 | 와이어쓰 | 플라스미노겐 활성화제 억제제-1의 억제제로서티아졸로-나프틸 산 |
WO2006023864A1 (en) | 2004-08-23 | 2006-03-02 | Wyeth | Pyrrolo-naphthyl acids as pai-1 inhibitors |
MX2007002178A (es) | 2004-08-23 | 2007-04-02 | Wyeth Corp | Acidos de oxazolo-naftilo como moduladores del inhibidor del activador de plasminogeno tipo 1 (pai-1) util en el tratamiento de trombosis y enfermedades cardiovasculares. |
AP2007003979A0 (en) * | 2004-11-23 | 2007-06-30 | Warner Lambert Co | 7-(2h-pyrazol-3-yl)-3,5-dihyroxy-heptanoic acid derivatives as hmg co-a reductase inhibitors for thetreatment of lipidemia |
MX2007008952A (es) | 2005-01-27 | 2007-09-18 | Wyeth Corp | Procesos y compuestos para la preparacion de derivados de naftilindol sustituidos. |
CA2605796A1 (en) * | 2005-04-25 | 2006-11-02 | Pfizer Products Inc. | Pharmaceutical compositions and methods comprising a combination of a selective estrogen receptor modulator and an aromatase inhibitor |
DE602006017217D1 (de) * | 2005-06-22 | 2010-11-11 | Pfizer Prod Inc | Stereoselektives hydrierverfahren zur herstellung von cis-6-phenyl-5-ä4-(2-pyrrolidin-1-yl-ethoxy)-phenylü-2-methoxy-5,6,7,8-tetrahydronaphthalin-hydrochlorid |
US8227476B2 (en) | 2005-08-03 | 2012-07-24 | Sprout Pharmaceuticals, Inc. | Use of flibanserin in the treatment of obesity |
CN101263115A (zh) | 2005-08-17 | 2008-09-10 | 惠氏公司 | 经取代吲哚和其用途 |
US7741317B2 (en) | 2005-10-21 | 2010-06-22 | Bristol-Myers Squibb Company | LXR modulators |
CA2626134C (en) | 2005-10-29 | 2013-12-24 | Boehringer Ingelheim International Gmbh | Benzimidazolone derivatives for the treatment of premenstrual and other female sexual disorders |
US20070105869A1 (en) * | 2005-11-08 | 2007-05-10 | Stephane Pollentier | Use of flibanserin for the treatment of pre-menopausal sexual desire disorders |
US7888376B2 (en) | 2005-11-23 | 2011-02-15 | Bristol-Myers Squibb Company | Heterocyclic CETP inhibitors |
JP5212931B2 (ja) * | 2006-01-26 | 2013-06-19 | 学校法人東京理科大学 | ラソフォキシフェン及びその類縁体の製造方法 |
MY151048A (en) * | 2006-05-09 | 2014-03-31 | Boehringer Ingelheim Int | Use of flibanserin for the treatment of post-menopausal sexual desire disorders |
US20090312242A1 (en) * | 2006-06-30 | 2009-12-17 | Ramiro Castro | Flibanserin for the treatment of urinary incontinence and related diseases |
US20090318469A1 (en) * | 2006-07-14 | 2009-12-24 | Boehringer Ingelheim International Gmbh | Use of Flibanserin for the Treatment of Sexual Disorders in Females |
CL2007002214A1 (es) | 2006-08-14 | 2008-03-07 | Boehringer Ingelheim Int | Composicion farmaceutica en la forma de comprimido, donde al menos la longitud del comprimido en el estado anterior de la aplicacion es al menos 7/12 del diametro pilorico del paciente y despues de ingerirlo en estado alimentado, la longitud del comp |
MX2009001551A (es) | 2006-08-14 | 2009-02-20 | Boehringer Ingelheim Int | Formulaciones de flibanserina y metodo para fabricarlas. |
WO2008022932A2 (en) * | 2006-08-25 | 2008-02-28 | Boehringer Ingelheim International Gmbh | Controlled release system and method for manufacturing the same |
ES2382009T3 (es) | 2006-12-01 | 2012-06-04 | Bristol-Myers Squibb Company | Derivados de N-((3-bencil)-2,2-(bis-fenil-)-propan-1-amina como inhibidores de CETP para el tratamiento de aterosclerosis y enfermedades cardiovasculares |
JP5087011B2 (ja) * | 2007-01-23 | 2012-11-28 | 馨 井上 | 眼疾患モデル用非ヒト動物 |
CZ2007373A3 (cs) * | 2007-05-29 | 2008-12-10 | Zentiva, A. S | Zpusob prípravy lasofoxifenu |
US20090062374A1 (en) * | 2007-08-29 | 2009-03-05 | Protia, Llc | Deuterium-enriched lasofoxifene |
UY31335A1 (es) * | 2007-09-12 | 2009-04-30 | Tratamiento de sintomas vasomotores | |
MY150082A (en) | 2007-10-16 | 2013-11-29 | Repros Therapeutics Inc | Trans-clomiphene for metabolic syndrome |
WO2009155481A1 (en) * | 2008-06-20 | 2009-12-23 | Gtx, Inc. | Metabolites of selective androgen receptor modulators and methods of use thereof |
EP2424839A4 (en) * | 2009-04-29 | 2012-10-17 | Glenmark Generics Ltd | PROCESS FOR THE PREPARATION OF LASOFOXIFEN TARTRATE |
WO2011159769A2 (en) | 2010-06-17 | 2011-12-22 | Aragon Pharmaceuticals, Inc. | Indane estrogen receptor modulators and uses thereof |
DE102010030538A1 (de) | 2010-06-25 | 2011-12-29 | Bayer Schering Pharma Aktiengesellschaft | 6,7-Dihydro-5H-benzo[7]annulen-Derivate, Verfahren zu ihrer Herstellung, pharmazeutische Präparate die diese enthalten, sowie deren Verwendung zur Herstellung von Arzneimitteln |
CN102311406A (zh) * | 2010-06-29 | 2012-01-11 | 武汉启瑞药业有限公司 | 拉索昔芬中间体的制备方法 |
CN102464629A (zh) * | 2010-11-12 | 2012-05-23 | 上海医药工业研究院 | 1-{2-[4-(6-甲氧基-2-苯基-3,4-二氢萘-1-基)苯氧基]乙基}吡咯烷的制备方法 |
EP2524908A1 (en) | 2011-05-20 | 2012-11-21 | LEK Pharmaceuticals d.d. | Process for the preparation of alfa-substituted ketones and their application in synthesis of pharmaceutically active compounds |
DE102011087987A1 (de) | 2011-12-08 | 2013-06-13 | Bayer Intellectual Property Gmbh | 6,7-Dihydro-5H-benzo[7]annulen-Derivate, Verfahren zu ihrer Herstellung, pharmazeutische Präparate die diese enthalten, sowie deren Verwendung zur Herstellung von Arzneimitteln |
CN102643178A (zh) * | 2012-02-08 | 2012-08-22 | 浙江华海药业股份有限公司 | 一种酒石酸拉索昔芬及其中间体的制备方法 |
CA2865234A1 (en) | 2012-02-29 | 2013-09-06 | Repros Therapeutics Inc. | Combination therapy for treating androgen deficiency |
CN103113323B (zh) * | 2013-02-05 | 2015-11-11 | 南京华威医药科技开发有限公司 | 酒石酸拉索昔芬中间体的制备方法 |
WO2015092634A1 (en) * | 2013-12-16 | 2015-06-25 | Novartis Ag | 1,2,3,4-tetrahydroisoquinoline compounds and compositions as selective estrogen receptor antagonists and degraders |
PT3122426T (pt) | 2014-03-28 | 2023-02-28 | Univ Duke | Tratamento de cancro da mama utilizando moduladores seletivos do recetor de estrogénio |
US9421264B2 (en) | 2014-03-28 | 2016-08-23 | Duke University | Method of treating cancer using selective estrogen receptor modulators |
HUE056199T2 (hu) | 2015-05-29 | 2022-01-28 | Eisai R&D Man Co Ltd | Tetraszubsztituált alkénvegyületek és alkalmazásuk |
CN108349952A (zh) * | 2015-11-09 | 2018-07-31 | 豪夫迈·罗氏有限公司 | 四氢萘雌激素受体调节剂及其用途 |
JP7048505B2 (ja) | 2015-11-10 | 2022-04-05 | パラクリン セラピューティクス エービー | Pdgf-cc阻害剤および抗エストロゲン剤によるer陰性乳癌の処置 |
CN109219604B (zh) * | 2016-04-08 | 2021-09-24 | 豪夫迈·罗氏有限公司 | 四氢异喹啉雌激素受体调节剂及其用途 |
SG11201903236SA (en) | 2016-10-11 | 2019-05-30 | Univ Duke | Lasofoxifene treatment of er+ breast cancer |
IL266003B (en) | 2016-11-28 | 2022-08-01 | Eisai R&D Man Co Ltd | Salts of indazole derivatives and their crystals |
CN111801098A (zh) | 2018-02-21 | 2020-10-20 | 人工智能治疗公司 | 使用阿匹莫德和谷氨酸能剂的组合疗法 |
EP3773524A4 (en) | 2018-04-10 | 2021-12-22 | Duke University | TREATMENT OF BREAST CANCER WITH LASOFOXIFEN |
CN109317203B (zh) * | 2018-12-03 | 2019-09-03 | 毕云丽 | 一种治疗绝经后妇女骨质疏松症用药物中间体的制备方法 |
GB202116903D0 (en) | 2021-11-18 | 2022-01-05 | Sermonix Pharmaceuticals Inc | Lasofoxifene treatment of aromatase-resistant er+ cancer |
Family Cites Families (31)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3396169A (en) * | 1966-10-26 | 1968-08-06 | Upjohn Co | Substituted 2-phenyl-1-(tertiary-aminoalkoxy) phenyl-3, 4-dihydronaphthalenes |
US3274213A (en) * | 1961-09-05 | 1966-09-20 | Upjohn Co | Alkoxy-substituted 2-phenyl-1-(tertiary-aminoalkoxy)phenyl-3, 4-dihydronaphthalenes |
US3234090A (en) * | 1962-09-10 | 1966-02-08 | Ciba Geigy Corp | Pharmaceutical compositions comprising saturated basic ethers |
US3227730A (en) * | 1963-05-01 | 1966-01-04 | Union Carbide Corp | Stabilization of lactones |
US3862232A (en) * | 1963-07-03 | 1975-01-21 | Upjohn Co | 1-(p-hydroxyphenyl)-2-phenyl-6-(2-diethylaminoethoxy)-3,4-dihydronaphthalene and the salts thereof |
US3293263A (en) * | 1963-12-09 | 1966-12-20 | Upjohn Co | Diphenylbenzocycloalkenes |
US3522319A (en) * | 1964-01-23 | 1970-07-28 | Ciba Geigy Corp | Phenol substituted tetrahydronaphthalenes useful as estrogenics |
US3320271A (en) * | 1964-06-01 | 1967-05-16 | Upjohn Co | 1, 2-diphenyl-3, 4-dihydronaphthalenes and 2, 3-diphenylindenes |
US3483293A (en) * | 1967-12-15 | 1969-12-09 | Upjohn Co | Method for controlling birds and rodents |
US3567737A (en) * | 1968-01-02 | 1971-03-02 | Upjohn Co | Derivatives of (2-cycloalkyl-1-phenyl-3,4-dihydronaphthalenes and) 2 - cycloalkyl - 1 - phenyl - 1,2,3,4 - tetrahydro-naphthalenes |
US3875242A (en) | 1968-01-02 | 1975-04-01 | Upjohn Co | Compounds and process for preparing the same |
US4133814A (en) * | 1975-10-28 | 1979-01-09 | Eli Lilly And Company | 2-Phenyl-3-aroylbenzothiophenes useful as antifertility agents |
US4358593A (en) * | 1981-04-03 | 1982-11-09 | Eli Lilly And Company | Process for preparing 3-(4-aminoethoxybenzoyl)benzo[b]thiophenes |
US4418068A (en) * | 1981-04-03 | 1983-11-29 | Eli Lilly And Company | Antiestrogenic and antiandrugenic benzothiophenes |
US4380635A (en) * | 1981-04-03 | 1983-04-19 | Eli Lilly And Company | Synthesis of acylated benzothiophenes |
DE4117512A1 (de) * | 1991-05-25 | 1992-11-26 | Schering Ag | 2-phenylbenzo(b)furane und -thiophene, verfahren zu deren herstellung und diese enthaltende pharmazeutische praeparate |
JP3157882B2 (ja) * | 1991-11-15 | 2001-04-16 | 帝国臓器製薬株式会社 | 新規なベンゾチオフエン誘導体 |
TW383306B (en) * | 1992-12-22 | 2000-03-01 | Lilly Co Eli | New use of 2-phenyl-3-aroylbenzothiophenes in lowering serum cholesterol |
US5482949A (en) * | 1993-03-19 | 1996-01-09 | Eli Lilly And Company | Sulfonate derivatives of 3-aroylbenzo[b]thiophenes |
US6756388B1 (en) * | 1993-10-12 | 2004-06-29 | Pfizer Inc. | Benzothiophenes and related compounds as estrogen agonists |
US6399634B1 (en) * | 1994-09-20 | 2002-06-04 | Eli Lilly And Company | Benzothiophene compounds, compositions, and methods |
US5552412A (en) * | 1995-01-09 | 1996-09-03 | Pfizer Inc | 5-substitued-6-cyclic-5,6,7,8-tetrahydronaphthalen2-ol compounds which are useful for treating osteoporosis |
US5510357A (en) * | 1995-02-28 | 1996-04-23 | Eli Lilly And Company | Benzothiophene compounds as anti-estrogenic agents |
US5532382A (en) * | 1995-03-13 | 1996-07-02 | Eli Lilly And Company | Benzothiophenes substituted at the 3-carbonyl |
US5567828A (en) * | 1995-06-07 | 1996-10-22 | Eli Lilly And Company | Compounds and compositions with nitrogen-containing non-basic side |
HN1996000101A (es) * | 1996-02-28 | 1997-06-26 | Inc Pfizer | Terapia combinada para la osteoporosis |
UA59384C2 (uk) * | 1996-12-20 | 2003-09-15 | Пфайзер, Інк. | Похідні сульфонамідів та амідів як агоністи простагландину, фармацевтична композиція та способи лікування на їх основі |
US6124314A (en) * | 1997-10-10 | 2000-09-26 | Pfizer Inc. | Osteoporosis compounds |
AU781168B2 (en) * | 2001-01-26 | 2005-05-12 | Pfizer Products Inc. | Method of treating certain cancers using an estrogen agonist/antagonist |
PL367094A1 (en) * | 2001-07-31 | 2005-02-21 | Pfizer Products Inc. | Pharmaceutical compositions, kits and methods comprising combinations of estrogen agonists/antagonists, estrogens and progestins |
DE102012218742A1 (de) | 2012-10-15 | 2014-04-17 | Deere & Company | Nachdrescheinrichtung für einen Mähdrescher |
-
1995
- 1995-01-09 US US08/369,954 patent/US5552412A/en not_active Ceased
- 1995-04-24 JP JP8521528A patent/JP2972347B2/ja not_active Expired - Lifetime
- 1995-04-24 DK DK95914493T patent/DK0802910T3/da active
- 1995-04-24 EP EP95914493A patent/EP0802910B1/en not_active Expired - Lifetime
- 1995-04-24 ES ES95914493T patent/ES2172579T3/es not_active Expired - Lifetime
- 1995-04-24 DE DE69525857T patent/DE69525857T2/de not_active Expired - Lifetime
- 1995-04-24 WO PCT/IB1995/000286 patent/WO1996021656A1/en active IP Right Grant
- 1995-04-24 PT PT95914493T patent/PT802910E/pt unknown
- 1995-04-24 DE DE122009000047C patent/DE122009000047I1/de active Pending
- 1995-04-24 EP EP20030026477 patent/EP1411049A1/en not_active Withdrawn
- 1995-04-24 AT AT95914493T patent/ATE214382T1/de active
- 1995-04-24 CA CA002209925A patent/CA2209925C/en not_active Expired - Lifetime
- 1995-04-24 EP EP01120246A patent/EP1151998A1/en not_active Withdrawn
- 1995-04-24 US US08/849,726 patent/US6204286B1/en not_active Expired - Lifetime
- 1995-12-14 AP APAP/P/1995/000774A patent/AP592A/en active
- 1995-12-22 SK SK1648-95A patent/SK281992B6/sk not_active IP Right Cessation
- 1995-12-22 CO CO95061202A patent/CO4600740A1/es unknown
- 1995-12-28 UA UA95125539A patent/UA46710C2/uk unknown
- 1995-12-30 TW TW084114170A patent/TW313567B/zh not_active IP Right Cessation
-
1996
- 1996-01-01 IL IL11664396A patent/IL116643A/xx not_active IP Right Cessation
- 1996-01-01 IL IL13076196A patent/IL130761A/xx not_active IP Right Cessation
- 1996-01-03 SG SG1996000020A patent/SG47377A1/en unknown
- 1996-01-03 MA MA24123A patent/MA23768A1/fr unknown
- 1996-01-03 PE PE1996000003A patent/PE46597A1/es not_active Application Discontinuation
- 1996-01-03 MY MYPI96000009A patent/MY115784A/en unknown
- 1996-01-04 AR ARP960100879A patent/AR003917A1/es unknown
- 1996-01-05 IS IS4316A patent/IS1916B/is unknown
- 1996-01-05 RU RU96100074A patent/RU2130454C1/ru active
- 1996-01-08 CZ CZ9655A patent/CZ285085B6/cs not_active IP Right Cessation
- 1996-01-08 CN CN96100634A patent/CN1059902C/zh not_active Expired - Lifetime
- 1996-01-08 RS YU596A patent/RS49531B/sr unknown
- 1996-01-08 PL PL96312182A patent/PL183474B1/pl unknown
- 1996-01-08 NZ NZ280792A patent/NZ280792A/en not_active IP Right Cessation
- 1996-01-08 NO NO960081A patent/NO305435B1/no not_active IP Right Cessation
- 1996-01-08 LV LVP-96-04A patent/LV11460B/en unknown
- 1996-01-08 ZA ZA9695A patent/ZA9695B/xx unknown
- 1996-01-08 RO RO96-00021A patent/RO116275B1/ro unknown
- 1996-01-08 KR KR1019960000199A patent/KR100190727B1/ko not_active IP Right Cessation
- 1996-01-09 EG EG1896A patent/EG23913A/xx active
- 1996-01-09 BR BR9600079A patent/BR9600079A/pt not_active IP Right Cessation
- 1996-01-09 BG BG100278A patent/BG62256B1/bg unknown
- 1996-01-09 OA OA60765A patent/OA10254A/en unknown
- 1996-01-09 HR HR960010A patent/HRP960010B1/xx not_active IP Right Cessation
- 1996-01-09 SI SI9600004A patent/SI9600004A/sl not_active IP Right Cessation
- 1996-01-09 AU AU40916/96A patent/AU700982B2/en not_active Expired
- 1996-01-09 TR TR96/00001A patent/TR199600001A2/xx unknown
- 1996-01-09 HU HU9600056A patent/HU224077B1/hu active Protection Beyond IP Right Term
- 1996-02-07 SA SA96160584A patent/SA96160584B1/ar unknown
-
1997
- 1997-07-08 FI FI972903A patent/FI116525B/fi not_active IP Right Cessation
-
1998
- 1998-08-28 US US09/141,613 patent/US6153622A/en not_active Expired - Lifetime
-
1999
- 1999-07-01 IL IL13076199A patent/IL130761A0/xx unknown
- 1999-12-17 US US09/466,034 patent/US6441193B1/en not_active Expired - Lifetime
-
2000
- 2000-10-24 IL IL13923500A patent/IL139235A0/xx unknown
-
2001
- 2001-03-28 US US09/820,158 patent/US20010025051A1/en not_active Abandoned
-
2002
- 2002-05-16 US US10/147,725 patent/US20020132816A1/en not_active Abandoned
-
2004
- 2004-12-23 US US11/022,427 patent/USRE39558E1/en not_active Expired - Lifetime
-
2009
- 2009-08-19 LU LU91599C patent/LU91599I2/fr unknown
- 2009-08-21 NO NO2009018C patent/NO2009018I2/no unknown
- 2009-08-24 NL NL300405C patent/NL300405I2/nl unknown
-
2010
- 2010-08-20 US US12/860,099 patent/US20100317712A1/en not_active Abandoned
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EG23913A (en) | Estrogen agonists / antagonists | |
ZA947911B (en) | Estrogen agonists | |
HU9603082D0 (en) | Neurokinine (tachykinine) antagonists | |
HU9603525D0 (en) | Vironectin receptor antagonists | |
HK1029574A1 (en) | 1-amino-alkylcyclohexane nmda receptor antagonists | |
IL116283A0 (en) | Estrogen agonists | |
AU7692996A (en) | Receptor antagonists | |
HU9601529D0 (en) | Pyrimidinedion-, pyrimidinetrion-, triazinedion-, tetrahydro-quinazolinedion- derivatives as alpha-adrenerg receptor antagonists | |
AU7396196A (en) | Kappa opioid receptor agonists | |
HU9600663D0 (en) | Endothelin-receptor antagonists | |
HU9601240D0 (en) | Beta-adrenerg agonists | |
HUP9700636A3 (en) | Novel estrogen receptor | |
HU9601176D0 (en) | Adhesion-receptor antagonists | |
AU6856796A (en) | Des-arg9-bk antagonists | |
AP9801212A0 (en) | Tetrahydroquin olinesas NMDA antagonists | |
HU9503191D0 (en) | Adhesion-receptor antagonists | |
IL131274A0 (en) | Estrogen agonists/antagonists | |
HU9602253D0 (en) | Endothelin-receptor antagonists | |
GB9719470D0 (en) | Nocotinic receptors |